Detalhe da pesquisa
1.
Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Hepatology
; 76(4): 951-966, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35076948
2.
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.
Gastroenterology
; 161(5): 1475-1486, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34310978
3.
Fatty acid synthesis suppresses dietary polyunsaturated fatty acid use.
Nat Commun
; 15(1): 45, 2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38167725
4.
Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy.
J Exp Clin Cancer Res
; 42(1): 92, 2023 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37072838
5.
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.
Sci Rep
; 12(1): 15661, 2022 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36123383
6.
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.
EClinicalMedicine
; 34: 100797, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33870151
7.
Fatty acid synthase - Modern tumor cell biology insights into a classical oncology target.
Pharmacol Ther
; 177: 23-31, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28202364
8.
p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.
Cancer Res
; 72(22): 5966-75, 2012 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22983922